Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia
Jonathan Friedberg, Director of Wilmot Cancer Institute, shared a recent article by Petra Langerbeins on X:
“Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: Phase III CLL12 Trial shows watch and wait still remains the standard. Journal of Clinical Oncology and The SWOG Cancer Research Network, S1925 trial is asking a similar question with venetoclax.”
Authors: Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf,Florian Simon, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Christof Schneider, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Mark-Oliver Zahn, Steffen Dörfel, Peter Staib, Timo Behlendorf, Manfred Hensel, Holger Hebart, Holger Klaproth, Andreas Block, Rüdiger Liersch, Ulrich Hauch, Bernhard Heinrich, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst and Michael Hallek
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023